APA
Czuczman M. S., Thall A., Witzig T. E., Vose J. M., Younes A., Emmanouilides C., Miller T. P., Moore J. O., Leonard J. P., Gordon L. I., Sweetenham J., Alkuzweny B., Finucane D. M. & Leigh B. R. (20050726). Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Chicago
Czuczman Myron S, Thall Aron, Witzig Thomas E, Vose Julie M, Younes Anas, Emmanouilides Christos, Miller Thomas P, Moore Joseph O, Leonard John P, Gordon Leo I, Sweetenham John, Alkuzweny Baha, Finucane Deborah M and Leigh Bryan R. 20050726. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Harvard
Czuczman M. S., Thall A., Witzig T. E., Vose J. M., Younes A., Emmanouilides C., Miller T. P., Moore J. O., Leonard J. P., Gordon L. I., Sweetenham J., Alkuzweny B., Finucane D. M. and Leigh B. R. (20050726). Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
MLA
Czuczman Myron S, Thall Aron, Witzig Thomas E, Vose Julie M, Younes Anas, Emmanouilides Christos, Miller Thomas P, Moore Joseph O, Leonard John P, Gordon Leo I, Sweetenham John, Alkuzweny Baha, Finucane Deborah M and Leigh Bryan R. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20050726.